Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

argenx SE - American Depositary Shares (NQ:ARGX)

795.96 -9.42 (-1.17%)
Streaming Delayed Price Updated: 10:46 AM EDT, Apr 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about argenx SE - American Depositary Shares

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Argenx Dives On Autoimmune Therapy Failure ↗
A treatment for a skin-blistering condition failed to beat a placebo. 
Via Investor's Business Daily
News headline image
FedEx Posts Downbeat Earnings, Joins Steelcase, argenx And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
U.S. stock futures were lower this morning, with the Dow Jones futures falling around 30 points on Wednesday. 
Via Benzinga
Topics Stocks
News headline image
Stifel Maintains Buy Rating for argenx: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
Here's How Much $1000 Invested In argenx 5 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
Analyst Ratings for argenx ↗
 
Via Benzinga
News headline image
These 2 Stocks Are Falling in a Fading Rally ↗
It's been a good month, but the stock market's looking tired. 
Via The Motley Fool
News headline image
$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
$1000 Invested In This Stock 5 Years Ago Would Be Worth $5,000 Today ↗
 
Via Benzinga
News headline image
Dow Jones Hits 2023 High, Nasdaq Slips; Tesla Cybertruck, Salesforce In Focus: Weekly Review ↗
Software earnings were strong, while the Fed is shifting toward rate cuts. 
Via Investor's Business Daily
Topics Economy Stocks
News headline image
Morgan Stanley Maintains Overweight Rating for argenx: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
Micron To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
News headline image
Earnings Outlook For argenx ↗
 
Via Benzinga
News headline image
Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years ↗
 
Via Benzinga
News headline image
Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years ↗
 
Via Benzinga
News headline image
Why SenesTech Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Shares of SenesTech, Inc. (NASDAQ: SNES) shares moved lower during Tuesday’s session after the company reported pricing of $5.0 million public offering. 
Via Benzinga
News headline image
Why Is Dutch Pharma Argenx Trading Lower Today? ↗
Tuesday, Argenx SE (NASDAQ: ARGX) released topline results from the ADVANCE-SC study evaluating Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in adults with primary immune thrombocytopenia... 
Via Benzinga
News headline image
Argenx Stock Crashes On An Unexpected Failure For Its Biggest Drug ↗
The company was hoping its drug would make a difference for patients with a rare blood disorder. 
Via Investor's Business Daily
News headline image
Why SpringWorks Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket ↗
Shares of SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) surged in pre-market trading after the company reported the FDA approval of OGSIVEO (nirogacestat) as the first and only treatment for adults... 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗
It's time to dive into the biggest pre-market stock movers for Tuesday morning with all of the latest news you need to know today! 
Via InvestorPlace
News headline image
Zscaler Posts Q1 Results, Joins argenx, Cool Company And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
U.S. stock futures traded mixed this morning, with the Dow Jones futures gaining around 15 points on Tuesday. 
Via Benzinga
Topics Stocks
News headline image
Antibody Player Dianthus Therapeutics Has Potential Amid Active M&A Landscape in Complement-Focused Firms: Analyst ↗
Wedbush initiated coverage on Dianthus Therapeutics Inc (NASDAQ: DNTH), noting its lead program DNTH103 as a well-positioned monoclonal antibody directed against the active form of the  
Via Benzinga
News headline image
Tech Titans Rising: 7 Underrated Stocks Set for Explosive Growth ↗
Are you looking to invest in rising tech stocks? Here are seven underrated stocks set for explosive growth. 
Via InvestorPlace
News headline image
Stock Market Rally Back In Force As Treasury Yields Plunge; Arista, Palantir Among Winners: Weekly Review ↗
Bulls are back in control as the major indexes confirmed the uptrend this week. 
Via Investor's Business Daily
News headline image
Argenx Comes Up With Big Sales Beat, Narrower-Than-Expected Losses ↗
The company sells Vyvgart, a treatment for generalized myasthenia gravis. 
Via Investor's Business Daily
Topics Earnings
News headline image
Stock Market Rally Attempt Underway; Micron, Nike, Amazon, Meta In Focus: Weekly Review ↗
But it's not a confirmed uptrend yet. Nike, Amazon and Meta were in focus. 
Via Investor's Business Daily
News headline image
What's Going On Pfizer's Subsidiary Biohaven Stock? ↗
Pfizer Inc's (NYSE: PFE) subsidiary Biohaven Ltd (NYSE: BHVN) released an  
Via Benzinga
News headline image
Biohaven, Yet Another Argenx Rival In Autoimmune Drugs, Just Rocketed 29% ↗
The companies hope by lowering immunoglobulin G, an antibody, that they can treat myriad autoimmune diseases. 
Via Investor's Business Daily
News headline image
Why Immunovant Stock Is Bolting Higher Today ↗
The company may have best-in-class autoimmune disease therapy under its roof. 
Via The Motley Fool
News headline image
Immunovant Parlays Its Shot At Rivaling Argenx Into A $300 Million Offering ↗
Both companies are working on drugs that lower an antibody tied to numerous autoimmune conditions. 
Via Investor's Business Daily
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.